RecruitingPhase 1NCT06565195
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
Sponsor: Prevail Therapeutics
Philadelphia, PA · +6 more sites
Parkinson's Disease clinical trials in Philadelphia, PA
29 recruiting parkinson's disease studies with a site in Philadelphia, PA.
All trials in Philadelphia, PA · All Parkinson's Disease trials
RecruitingPhase not listedNCT04997642
Parkinson's Disease and Movement Disorders Clinical Database
Sponsor: University of Pennsylvania
Philadelphia, PA
RecruitingPhase 3NCT06312176
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Sponsor: Merck Sharp & Dohme LLC
Philadelphia, PA · +45 more sites
RecruitingPhase 3NCT06952504
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Sponsor: Merck Sharp & Dohme LLC
Bethlehem, PA · Philadelphia, PA · +50 more sites
RecruitingPhase 3NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Sponsor: AstraZeneca
Abington, PA · Hershey, PA · Philadelphia, PA · +60 more sites
RecruitingPhase 3NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Sponsor: Merck Sharp & Dohme LLC
Philadelphia, PA · Willow Grove, PA · +28 more sites
RecruitingPhase 2NCT06996652
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
Sponsor: Yale University
Philadelphia, PA · +17 more sites
RecruitingPhase 3NCT07174310
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Sponsor: Hoffmann-La Roche
Philadelphia, PA · Pittsburgh, PA · +51 more sites
RecruitingPhase 2NCT06680830
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Sponsor: Neuron23 Inc.
Philadelphia, PA · +44 more sites
RecruitingPhase 2NCT07002034
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Sponsor: Reunion Neuroscience Inc
Philadelphia, PA · +31 more sites
RecruitingPhase not listedNCT04994015
Parkinson's Foundation PD GENEration Genetic Registry
Sponsor: Parkinson's Foundation
Philadelphia, PA · Pittsburgh, PA · +60 more sites
RecruitingPhase not listedNCT07330258
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
Sponsor: Bayer
Philadelphia, PA · +26 more sites
RecruitingPhase not listedNCT07798700
Biofluid Research on Age-Related or Inherited Neurodegeneration
Sponsor: University of Pennsylvania
Philadelphia, PA
RecruitingPhase 1 / Phase 2NCT04165070
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Sponsor: Merck Sharp & Dohme LLC
Philadelphia, PA · +17 more sites
RecruitingPhase not listedNCT04165798
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Sponsor: Merck Sharp & Dohme LLC
Philadelphia, PA · +17 more sites
RecruitingPhase 4NCT04373317
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Sponsor: VA Office of Research and Development
Philadelphia, PA · +22 more sites
RecruitingNot applicableNCT06377033
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Sponsor: University of Pennsylvania
Philadelphia, PA
RecruitingPhase not listedNCT04477785
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Sponsor: Michael J. Fox Foundation for Parkinson's Research
Philadelphia, PA · Pittsburgh, PA · +28 more sites
RecruitingEarly Phase 1NCT06303921
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
Sponsor: University of Pennsylvania
Philadelphia, PA · +2 more sites
RecruitingPhase not listedNCT05539196
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
Sponsor: InSightec
Philadelphia, PA · +3 more sites
RecruitingPhase not listedNCT04071847
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
Sponsor: Abbott Medical Devices
Exton, PA · Philadelphia, PA · Pittsburgh, PA · +20 more sites
RecruitingEarly Phase 1NCT06932809
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
Sponsor: University of Pennsylvania
Philadelphia, PA · +1 more sites
RecruitingPhase 2NCT07265596
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
Sponsor: Michael J. Fox Foundation for Parkinson's Research
Philadelphia, PA · +1 more sites
RecruitingEarly Phase 1NCT06032026
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
Sponsor: University of Pennsylvania
Philadelphia, PA
RecruitingNot applicableNCT05070013
Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)
Sponsor: University of Nebraska
Philadelphia, PA · +1 more sites
Not yet recruitingPhase 4NCT07187466
Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease
Sponsor: VA Office of Research and Development
Philadelphia, PA · +2 more sites
Not yet recruitingNot applicableNCT07286994
Gamification and Physical Activity in PD
Sponsor: VA Office of Research and Development
Philadelphia, PA
Not yet recruitingNot applicableNCT07781696
CnF-DBS for Levodopa-Resistant FOG
Sponsor: Iahn Cajigas
Philadelphia, PA · +2 more sites
Not yet recruitingPhase 4NCT07627529
Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease
Sponsor: Corporal Michael J. Crescenz VA Medical Center
Philadelphia, PA
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.